Volume 72, Issue 6
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Volunteers vaccinated with a candidate malaria vaccine containing merozoite surface protein 1 (MSP-1) exhibit antibodies to MSP-1 that are measured by enzyme-linked immunosorbent assay (ELISA). The purpose of this study was to make a human reference standard for MSP-1 antibody measured in absolute quantity units using pooled plasma samples known to contain high titers of MSP-1 antibody based on previous ELISA results. Immobilized metal affinity chromatography was used to determine the amount of MSP-1 antibody in this plasma pool. Hexahistidine-tagged MSP-1 antigen adsorbed to nickel-chelating resin was used to capture MSP-1 antibody from the plasma pool. The intact MSP-1 antibody-antigen complexes were eluted and total IgG was measured by an ELISA standardized against purified human IgG. In this way, the human reference standard was determined to contain 48.3 μg/mL of MSP-1 antibody. This reference standard may be useful as a quantitative working standard for measuring MSP-1 antibody response in future vaccine clinical trials involving MSP-1.


Article metrics loading...

Loading full text...

Full text loading...



  1. Moorthy V, Hill AV, 2002. Malaria vaccines. Br Med Bull 62 : 59–72.
  2. Lyon JA, Haynes JD, Diggs CL, Chulay JD, Haidaris CG, Pratt-Rossiter J, 1987. Monoclonal antibody characterization of the 195-kilodalton major surface glycoprotein of Plasmodium falciparum malaria schizonts and merozoites: identification of additional processed products and a serotype-restricted repetitive epitope. J Immunol 138 : 895–901.
  3. Blackman MJ, Ling IT, Nicholls SC, Holder AA, 1991. Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol 49 : 29–33.
  4. Blackman MJ, Heidrich HG, Donachie S, McBride JS, Holder AA, 1990. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172 : 379–382.
  5. Morgan WD, Birdsall B, Frenkiel TA, Gradwell MG, Burghaus PA, Syed SE, Uthaipibull C, Holder AA, Feeney J, 1999. Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J Mol Biol 289 : 113–122.
  6. Uthaipibull C, Aufiero B, Syed SE, Hansen B, Guevara Patino JA, Angov E, Ling IT, Fegeding K, Morgan WD, Ockenhouse C, Birdsall B, Feeney J, Lyon JA, Holder AA, 2001. Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol 307 : 1381–1394.
  7. O’Donnell RA, de Koning-Ward TF, Burt RA, Bockarie M, Reeder JC, Cowman AF, Crabb BS, 2001. Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med 193 : 1403–1412.
  8. Carvalho LJ, Daniel-Ribeiro CT, Goto H, 2002. Malaria vaccine: candidate antigens, mechanisms, constraints and prospects. Scand J Immunol 56 : 327–343.
  9. Daly TM, Long CA, 1995. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 155 : 236–243.
  10. Hirunpetcharat C, Tian JH, Kaslow DC, van Rooijen N, Kumar S, Berzofsky JA, Miller LH, Good MF, 1997. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. J Immunol 159 : 3400–3411.
  11. Chang SP, Case SE, Gosnell WL, Hashimoto A, Kramer KJ, Tam LQ, Hashiro CQ, Nikaido CM, Gibson HL, Lee-Ng CT, Barr PJ, Yokota BT, Hut GS, 1996. A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria. Infect Immun 64 : 253–261.
  12. Kumar S, Collins W, Egan A, Yadava A, Garraud O, Blackman MJ, Guevara Patino JA, Diggs C, Kaslow DC, 2000. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 68 : 2215–2223.
  13. Singh S, Kennedy MC, Long CA, Saul AJ, Miller LH, Stowers AW, 2003. Biochemical and immunological characterization of bacterially expressed and refolded Plasmodium falciparum 42-kilodalton C-terminal merozoite surface protein 1. Infect Immun 71 : 6766–6774.
  14. Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, Holder AA, Riley EM, 1996. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis 173 : 765–769.
  15. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L, Wirtz RA, Sadoff JC, Kaslow DC, Kumar S, Church LWP, Crutcher JM, Wizel B, Hoffman S, Lalvani A, Hill AVS, Tine JA, Guito KP, de Taisne C, Anders R, Horii T, Paoletti E, Ballou WR, 1998. Phase I/IIa safety, immunogenicity, and efficacy trial of NY-VAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177 : 1664–1673.
  16. Keitel WA, Kester KE, Atmar RL, White AC, Bond NH, Holland CA, Krzych U, Palmer DR, Egan A, Diggs C, Ballou WR, Hall BF, Kaslow D, 1999. Phase I trial of two recombinant vaccines containing the 19kd carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine 18 : 531–539.
  17. Angov E, Aufiero BM, Turgeon AM, Van Handenhove M, Ockenhouse CF, Kester KE, Walsh DS, McBride JS, Dubois MC, Cohen J, Haynes JD, Eckels KH, Heppner DG, Ballou WR, Diggs CL, Lyon JA, 2003. Development and pre-clinical analysis of a Plasmodium falciparum merozoite surface protein-1(42) malaria vaccine. Mol Biochem Parasitol 128 : 195–204.
  18. Raux M, Finkielsztejn L, Salmon-Ceron D, Bouchez H, Excler JL, Dulioust E, Grouin JM, Sicard D, Blondeau C, 1999. Development and standardization of methods to evaluate the antibody response to an HIV-1 candidate vaccine in secretions and sera of seronegative vaccine recipients. J Immunol Methods 222 : 111–124.
  19. Ueda EK, Gout PW, Morganti L, 2003. Current and prospective applications of metal ion-protein binding. J Chromatogr A 988 : 1–23.
  20. Sawadogo M, van Dyke MW, 1995. Indirect use of immobilized metal affinity chromatography for isolation and characterization of protein partners. Genet Eng (N Y) 17 : 53–65.
  21. Hale JE, Beidler DE, 1994. Purification of humanized murine and murine monoclonal antibodies using immobilized metal-affinity chromatography. Anal Biochem 222 : 29–33.
  22. Tishchenko G, Hodrova B, Simunek J, Bleha M, 2003. Nickel and copper complexes of a chelating methacrylate sorbent in the purification of chitinases and specific immunoglobulin G1 by immobilized metal ion affinity chromatography. J Chromatogr A 983 : 125–132.
  23. Nwuba RI, Sodeinde O, Anumudu CI, Omosun YO, Odaibo AB, Holder AA, Nwagwu M, 2002. The human immune response to Plasmodium falciparum includes both antibodies that inhibit merozoite surface protein 1 secondary processing and blocking antibodies. Infect Immun 70 : 5328–5331.
  24. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, Egwang TG, Holder AA, Riley EM, 2004. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun 72 : 1557–1567.

Data & Media loading...

  • Received : 11 Aug 2004
  • Accepted : 07 Oct 2004

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error